CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma.

IF 3.5 3区医学

International Journal of Immunopathology and Pharmacology Pub Date : 2024-01-01 DOI:10.1177/03946320241227312

Xiaohu Lin, Xiaomei Zhao, Yiming Chen, Rong Yang, Zhenlin Dai, Wei Li, Chengzhong Lin, Wei Cao

{"title":"CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma.","authors":"Xiaohu Lin, Xiaomei Zhao, Yiming Chen, Rong Yang, Zhenlin Dai, Wei Li, Chengzhong Lin, Wei Cao","doi":"10.1177/03946320241227312","DOIUrl":null,"url":null,"abstract":"Objectives: This study aims to systematically explore the role of chemokine CXC ligand 13 (CXCL13) in head and neck squamous cell carcinoma (HNSCC). Methods: The Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases provided the RNA-seq data for cancer and normal tissues, respectively. Gene set enrichment analysis was applied to search the cancer hallmarks associated with CXCL13 expression. TIMER2.0 was the main platform used to investigate the immune cell infiltration related to CXCL13. Immunohistochemistry was applied to explore the relationship between CXCL13 and patients' prognosis and the relationship between CXCL13 and tertiary lymphoid structures (TLSs). Results: The expression of CXCL13 was upregulated in most tumors, including HNSCC. The higher expression of CXCL13 was closely related to the positive prognosis of HNSCC. CXCL13 was mainly expressed in B cells and CD8 + T cells, revealing the relationship between its expression and immune activation in the tumor microenvironment. Furthermore, immunohistochemistry and multiple fluorescence staining analysis of HNSCC samples showed a powerful correlation between CXCL13 expression, TLSs formation, and positive prognosis. Finally, CXCL13 significantly increased the response to cancer immunotherapy. Conclusions: CXCL13 may function as a potential biomarker for predicting prognosis and immunotherapy response and associate with TLSs in HNSCC.","PeriodicalId":48647,"journal":{"name":"International Journal of Immunopathology and Pharmacology","volume":"38 ","pages":"3946320241227312"},"PeriodicalIF":3.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807398/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Immunopathology and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03946320241227312","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aims to systematically explore the role of chemokine CXC ligand 13 (CXCL13) in head and neck squamous cell carcinoma (HNSCC). Methods: The Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases provided the RNA-seq data for cancer and normal tissues, respectively. Gene set enrichment analysis was applied to search the cancer hallmarks associated with CXCL13 expression. TIMER2.0 was the main platform used to investigate the immune cell infiltration related to CXCL13. Immunohistochemistry was applied to explore the relationship between CXCL13 and patients' prognosis and the relationship between CXCL13 and tertiary lymphoid structures (TLSs). Results: The expression of CXCL13 was upregulated in most tumors, including HNSCC. The higher expression of CXCL13 was closely related to the positive prognosis of HNSCC. CXCL13 was mainly expressed in B cells and CD8 + T cells, revealing the relationship between its expression and immune activation in the tumor microenvironment. Furthermore, immunohistochemistry and multiple fluorescence staining analysis of HNSCC samples showed a powerful correlation between CXCL13 expression, TLSs formation, and positive prognosis. Finally, CXCL13 significantly increased the response to cancer immunotherapy. Conclusions: CXCL13 may function as a potential biomarker for predicting prognosis and immunotherapy response and associate with TLSs in HNSCC.

查看原文本刊更多论文

CXC 配体 13 可协调免疫活性微环境，增强头颈部鳞状细胞癌的免疫疗法反应。

研究目的本研究旨在系统探讨趋化因子 CXC 配体 13（CXCL13）在头颈部鳞状细胞癌（HNSCC）中的作用。研究方法基因型-组织表达（GTEx）和癌症基因组图谱（TCGA）数据库分别提供了癌症和正常组织的RNA-seq数据。基因组富集分析用于搜索与CXCL13表达相关的癌症特征。TIMER2.0是研究与CXCL13相关的免疫细胞浸润的主要平台。免疫组化技术用于探讨CXCL13与患者预后的关系，以及CXCL13与三级淋巴结构（TLSs）的关系。结果发现CXCL13在包括HNSCC在内的大多数肿瘤中表达上调。CXCL13的高表达与HNSCC的阳性预后密切相关。CXCL13 主要在 B 细胞和 CD8 + T 细胞中表达，揭示了其表达与肿瘤微环境中免疫激活之间的关系。此外，对HNSCC样本进行的免疫组化和多重荧光染色分析表明，CXCL13的表达、TLSs的形成和阳性预后之间存在密切联系。最后，CXCL13 能明显增加癌症免疫疗法的反应。结论CXCL13可能是预测HNSCC预后和免疫治疗反应的潜在生物标记物，并与TLSs相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Immunopathology and Pharmacology Immunology and Microbiology-Immunology

自引率

0.00%

发文量

期刊介绍： International Journal of Immunopathology and Pharmacology is an Open Access peer-reviewed journal publishing original papers describing research in the fields of immunology, pathology and pharmacology. The intention is that the journal should reflect both the experimental and clinical aspects of immunology as well as advances in the understanding of the pathology and pharmacology of the immune system.